OUR MISSION

The National Foundation for Cancer Research (NFCR) was founded in 1973 to support cancer research in the laboratory. NFCR research, conducted at both the cellular and molecular levels, is leading to better prevention, earlier diagnosis, new treatments and eventually a cure for cancer.

By supporting the best ideas of the best minds and by facilitating collaboration among NFCR scientists, advances in one field contribute to discoveries in another. This is what NFCR’s “Laboratory Without Walls” makes possible.

Taylor Daley, 6 years old
It’s about saving lives.

TABLE OF CONTENTS

President’s Message ............... 1
NFCR Screensaver- Lifesaver Project ............... 2
NFCR Supported Scientists .......... 4
Biofunding Summit 2003 .......... 7
New Frontiers in Targeted Cancer Therapies .... 8
Special Events .................. 9
NFCR Partnerships ............... 10
NFCR Rose Fund ............... 11
How to Make a Gift ............... 12
Independent Auditors’ Report ... 13
Financial Statements ............ 14
Notes to Financial Statements ... 16
Contributors to a Cure ........... 21
I am pleased to present you with the 2004 Annual Report of the National Foundation for Cancer Research (NFCR). For over 30 years, NFCR has been dedicated to funding basic science cancer research that is now being translated into better treatments and new therapies for patients and ultimately, will lead to the cure for cancer.

Today we are at the dawn of a new era in diagnosing and treating cancer – all types of cancer. NFCR’s support of basic science cancer research has helped scientists unravel much of the basic molecular biology of cancer. That understanding has now reached the point where it can be turned into action.

Nowhere is this more evident than in the role NFCR has played in advancing targeted cancer therapies. We now have the means to develop targeted treatments for cancers at the “molecular level” where they can be cured. This will mean that cancer treatments can be administered to those individuals for whom it will actually work, and more people can be treated successfully. Similarly, molecular and genetic knowledge will reveal who is most likely to suffer side effects, and that information will be considered when treatments are prescribed.

We are proud of the role NFCR has played in advancing cancer research for the past 30 years, however there is still much more work to do. That is why we are more committed than ever to funding innovative research and to accelerating the pace at which new therapies and drugs are brought to cancer patients who need them most.

To all of you who support NFCR, thank you. At the National Foundation for Cancer Research, we take our accountability to our donors seriously. Together, we will work to prevent and cure all types of cancer.

Sincerely,

Franklin C. Salisbury, Jr.
President
Since 1973, NFCR has been a catalyst for fostering synergistic collaborations between cancer researchers worldwide.

NFCR is about Research for a Cure. When NFCR scientists make an initial discovery, we proactively connect them with other researchers who can provide the additional expertise and resources necessary to bring that discovery from the lab to the patient's bedside as quickly as possible.

In 2004, two of NFCR's Discovery Centers joined forces to bring hope to pancreatic cancer patients – working together to accelerate the oftentimes long and expensive drug discovery process.

Less than three years ago, scientists at the NFCR Center for Computational Drug Discovery at the University of Oxford in England launched a new research program, the Screensaver-Lifesaver Project. Working in partnership with United Devices and Accelrys along with support from the Intel Corporation, scientists at this NFCR Center developed the capability to utilize the GRID computing technology platform for drug screening. This technology allows idle computer time from individual personal computers to be linked via the internet and converted into enormous computing power, screening billions of small molecules against protein targets that are relevant to various cancer types.

The goal of this initiative is to accelerate the new drug screening process, significantly reducing the time needed to bring new anti-cancer drugs to patients.

Three years later, 3 million computer users around the world have now downloaded this program, creating the world's largest virtual supercomputer capable of performing more than 50 trillion operations per second. Today, the NFCR Center for Computational Drug Discovery has more computer power for drug discovery research than does all of the pharmaceutical industry combined.

Currently, scientists at the NFCR Center for Computational Drug Discovery are using this computer power to screen drug targets discovered by other NFCR researchers to greatly accelerate the pace of cancer research, and move discoveries from the laboratory bench to clinical trials and cancer patients. One example is NFCR's Pancreatic Cancer Research Collaboration Initiative.

Every year, nearly 30,000 people are diagnosed with pancreatic cancer in the United States alone. Most die from the disease. Pancreatic cancer has the lowest survival rate of all types of malignancies and is the fourth leading cause of death from cancer.
Of those individuals diagnosed with pancreatic cancer in 2004, only 24% will still be alive in 2005. Moreover, currently available treatment options for pancreatic cancer are limited and not very effective. Most of the potential new drugs are still at the experimental stage or remain in research laboratories. Unfortunately, pancreatic cancer patients simply do not have time to wait the ten years or more it takes for new drugs to reach them.

Like so many other cancers, the earlier it’s caught, the greater the chances of survival. However, there is no screening test available for pancreatic cancer. By the time symptoms appear, it’s usually too late for a cure.

These frightening statistics underscore just how important it is to come up with new and better therapies to treat pancreatic cancer. The process for pancreatic cancer drug development must be accelerated.

At the NFCR Center for New Therapies Development in Tucson, Arizona, co-Directors Dr. Daniel Von Hoff and Laurence Hurley have identified several new protein targets that are related to the development of pancreatic cancer: the Aurora A Kinase, Aurora B Kinase, PRL-1 Phosphatase, and Urokinase-type Plasminogen Activator (uPA). These protein targets have been confirmed to be involved in the progression and invasion of pancreatic cancer and other types of cancers, and novel anti-cancer agents can be developed by discovering specific inhibitors of these proteins.

To develop effective drugs targeting these newly identified cancer proteins, Drs. Von Hoff and Hurley are racing against time. They could not have found a stronger collaborator than Dr. Graham Richards at the NFCR Center for Computational Drug Discovery at Oxford. The collaboration between these two centers is creating tremendous scientific synergies and is greatly accelerating the pace at which novel drugs to treat pancreatic cancer can be found.

**NFCR’s Screensaver is truly a Lifesaver.**

It is all being made possible by NFCR donors who believed in us. With the powerful international network of NFCR Discovery Centers and the collaborations between scientists worldwide, cancer research is being dramatically changed.

We believe this cross-center collaboration organized by NFCR is a tremendous advancement for how medical and cancer research should be conducted.

Join over 3 million NFCR supporters worldwide to participate in our Screensaver-Lifesaver Project and use your computer to help find a cure for cancer. Visit [www.NFCR.org](http://www.NFCR.org) to download the free screensaver program.
NFCR RESEARCHERS FUNDED IN 2004

NFCR Research Discovery Centers

**NFCR Center for Genomics and Nutrition**
*University of California, Berkeley, CA*
*Children’s Hospital Oakland Research Center, Oakland, CA*
Bruce N. Ames, Ph.D.
Martyn T. Smith, Ph.D.
Nina T. Holland, Ph.D.
Mark K. Shigenaga, Ph.D.

**NFCR Center for Protein and Nucleic Acid Chemistry**
*Yale University, New Haven, CT*
Alanna Schepartz, Ph.D.
Donald M. Crothers, Ph.D.

**NFCR Center for New Therapies Development**
*Arizona Cancer Center, Tucson, AZ*
Daniel D. Von Hoff, M.D.
Laurence Hurley, Ph.D.

**NFCR Center for RNA Cancer Research**
*Freie Universität Berlin, Germany*
Volker A. Erdmann, Ph.D.
Jens Peter Fürste, Ph.D.
Rolfe Bald, Ph.D.

**NFCR Center for Metastasis Research**
*University of Alabama, Birmingham, AL*
Danny R. Welch, Ph.D.
Andrea Mastro, Ph.D.
Carol V. Gay, Ph.D.
Henry J. Donahue, Ph.D.
Carrie W. Rinker-Schaeffer, Ph.D.

**NFCR Center for Molecular Analysis and Imaging**
*Massachusetts General Hospital, Boston, MA*
Ralph Weissleder, M.D., Ph.D.
James P. Basilion, Ph.D.

**NFCR Center for Computational Drug Discovery**
*University of Oxford, Oxford, UK*
W. Graham Richards, D.Sc.
Federico Gago, Ph.D.
Christopher A. Reynolds, Ph.D.
M. Cristina Menziani, Ph.D.
Maria J. Ramos, Ph.D.

**NFCR Center for Molecular Oncology**
*Institute of Medicinal Biotechnology, Beijing, China*
Jian-Dong Jiang, M.D., Ph.D.
Yong-Su Zhen, Ph.D.
Rong-Guang Shao, Ph.D.

**NFCR Center for Therapeutic Antibody Engineering**
*Dana-Farber Cancer Institute, Cambridge, MA*
Wayne A. Marasco, M.D., Ph.D.

NFCR Fellows

**Webster Cavenee, Ph.D.**
*Ludwig Institute for Cancer Research*
Identifying genes whose mutation or altered expression leads to malignant tumors of the brain and muscle.

**Yung-Chi Cheng, Ph.D.**
*Yale University School of Medicine*
Exploring a Chinese medicinal formula discovered to decrease hematological side effects and enhance anti-tumor activity for a variety of anti-cancer drugs.
Curt I. Civin, M.D.
Johns Hopkins School of Medicine
Understanding how the survival, proliferation, and differentiation of normal and malignant leukemia cells are regulated and translating the results into useful clinical tools.

Stanley N. Cohen, M.D.
Stanford University School of Medicine
Elucidation of the genetic control of tumorigenesis and cancer metastasis.

Harold F. Dvorak, M.D.
Beth Israel Deaconess Medical Center
Elucidating the steps and mechanisms of tumor angiogenesis and contrasting these with the steps and mechanisms by which normal blood vessels form.

Waun Ki Hong, M.D.
MD Anderson Cancer Center
Studying the drug celecoxib in a clinical trial for the chemoprevention of lung cancer.

Susan Band Horwitz, Ph.D.
Albert Einstein College of Medicine
Searching for natural products that are analogues of Taxol that circumvent the problem of tumor multi-drug resistance.

Paul Schimmel, Ph.D.
The Scripps Research Institute
Understanding how components of the genetic code function in signal transduction pathways in ways that can be used to treat cancers.

Helmut Sies, M.D.
Heinrich-Heine-Universität
Addressing the underlying mechanism and biological impact of DNA damage related to ultraviolet radiation that give rise to skin cancer, and the defense systems repairing such damage.

I. Bernard Weinstein, M.D.
Columbia-Presbyterian Medical Center
Exploring abnormalities in the circuitry that controls cell cycle progression and signal transduction in cancer cells and using these insights to develop naturally occurring and synthetic compounds that can be used in cancer prevention and therapy.

Rebecca W. Alexander, Ph.D.
Wake Forest University
Understanding protein-nucleic acid interactions that are fundamental to cellular processes in both normal and tumor cells.

Jacqueline K. Barton, Ph.D.
California Institute of Technology
Understanding the consequences of DNA charge transport chemistry with respect to how DNA is damaged and repaired.

Robert Bast, Jr., M.D.
MD Anderson Cancer Center
Identifying novel tumor suppressor genes in epithelial ovarian cancer.

Joseph R. Bertino, M.D.
The Cancer Institute of New Jersey
Determining if sequential administration of a low dose of flavopiridol, a cyclin dependent kinase inhibitor, can sensitize small cell lung cancer cells to another drug, doxorubicin.
Esther H. Chang, Ph.D.
Georgetown University
Exploring chemosensitization of breast cancer cells by systemic delivery of anti-HER2 oligonucleotides.

Laurence J. N. Cooper, M.D., Ph.D.
City of Hope National Medical Center
Evaluating the anti-lymphoma effects of combining CD19-specific human white blood cells, with CD20-specific immunocytokines.

Donald M. Engelman, Ph.D.
Yale University
Researching the possible roles of membrane helix interactions in viral carcinogenesis.

Daniel A. Haber, M.D., Ph.D.
Massachusetts General Hospital Cancer Center
Discovering new tumor suppressor genes implicated in cancer progression using Representational Difference Analysis.

Kathryn B. Horwitz, Ph.D.
University of Colorado Health Science Center
Understanding the role of estrogen, progesterone and their receptors in breast cancer.

John G. Koland, Ph.D.
University of Iowa
Understanding the impact of epidermal growth factor receptors on the disease process and therapeutic strategies for breast cancer.

Janos Ladik, Ph.D.
University Erlangen-Nurnberg
Investigating the cancer prevention effects of DNA intercalating agents.

Lawrence J. Marnett, Ph.D.
Vanderbilt University Medical Center
Understanding the role of endocannabinoids on the growth and differentiation of colon carcinoma cells as well as normal keratinocytes.

Terence H. Rabbitts, Ph.D., FRS
MRC Laboratory of Molecular Biology
Developing anti-RAS intrabodies as anti-cancer reagents, which can block cancerous cell growth, invasion or metastasis in vivo.

Alan C. Sartorelli, Ph.D.
Yale University School of Medicine
Understanding the role of the transcription factor Scl in sensitivity of leukemia cells to all-trans retinoic acid induced differentiation.

Michael B. Sporn, M.D.
Dartmouth Medical School
Developing new triterpenoid compounds for the prevention of cancer through their anti-proliferative and anti-inflammatory properties.
Three decades ago, President Richard Nixon committed the federal government to curing cancer. While signing legislation that would direct over $100 million toward cancer research, Nixon said, “The time has come in America when the same kind of concentrated effort that split the atom and took man to the moon should be turned toward curing this dreaded disease. Let us make a total national commitment to achieve this goal. America has long been the wealthiest nation in the world. Now it is time we became the healthiest nation in the world.”

But there was only so much the federal government could do. Harkening to President Nixon’s call for a national commitment to defeat cancer, scientists and business leaders alike joined together to found the National Foundation for Cancer Research. NFCR would serve as a catalyst for scientific discoveries in the laboratory.

Cancer research in the laboratory – this is where cancer will be cured. And to make sure the discoveries being made by scientists in the laboratory get to doctors and patients at their bedsides, NFCR invited researchers, biopharmaceutical investors and business leaders to the Biofunding Summit 2003: New Frontiers in Cancer Research conference in Phoenix, Arizona.

Co-hosted by two other forward-thinking organizations, the International Genomics Consortium and The Scientist magazine, three days of presentations highlighted the current breakthroughs in cancer research and treatments and provided a forum for collaboration and exchange. A “think tank” of leaders from around the world, including cancer researchers and members of the biotech/pharmaceutical sector, gathered to discuss opportunities and challenges in cancer drug discovery and development.

Among the highlights, Dr. Daniel Von Hoff, co-Director of the NFCR Center for New Therapies Development in Tucson, Arizona, presented a detailed overview of the most promising anti-cancer therapies in the pipeline – providing inspiration and hope for everyone. Another presenter, NFCR Fellow Dr. Stanley Cohen, co-inventor of recombinant DNA technology which heralded the biotech revolution in medicine, described his most recent work in the discovery of molecular targets to defeat cancer. Dr. Cohen’s research could be one of the most important discoveries in the improvement of diagnosing and treating cancer patients.

In all, over 30 scientists presented discoveries that hold significant promise in the war against cancer. Thirty years of progress has only inspired us to look forward to the opportunities and overcoming the challenges that lie ahead.
The human genome has been mapped, and with “targeted therapies” we are now at the dawn of a new era of diagnosing and treating cancers. This is a revolution in medicine, and for the first time in a long time, oncologists are genuinely excited about the possibility that “personalized medicine” may soon become a reality for cancer patients.

Two recent examples of targeted therapies are found in the combination of new anti-cancer drugs. Avastin™ and Tarceva™ have been shown to provide a “one-two” punch against non-small cell lung cancer, the nation’s leading cancer killer. And results of a phase III clinical trial show that Tarceva™ in combination with another anti-cancer drug, Gemcitabine™, also works against pancreatic cancer.

Targeted therapies are making a difference for patients with cancer, both by improving their chances of survival and also their quality of life. Heralded as a new paradigm for treating cancers, what is particularly important about targeted therapies is that many of these treatments are targeted more accurately toward tumor cells than normal cells and hence have a bigger impact against cancer with less toxicity. What is also important, but what may not be so obvious, is the tremendous role that the National Foundation for Cancer Research has played in the development of these targeted therapies.

There are multiple examples of the impact NFCR has made throughout 30 years of funding cutting-edge cancer research in the laboratory. In addition to research that led to the development of both Tarceva™ and Avastin™, here are a few more selected examples which have had an enormous impact on the care of patients with cancer today.

- **In the 1980s**, NFCR Project Director, Dr. Dennis Carson, at the University of California, San Diego, found that a certain purine nucleoside agent selectively killed hairy cell leukemia cells. This development, resulting in the drug Cladrabine™, was also a landmark breakthrough for patients with hairy cell leukemia. Indeed it is curative in most instances and his research is directly attributable to NFCR’s funding.

- **Additionally**, NFCR Project Director, Dr. Gordon Sato, at the W. Alton Jones Cell Science Center developed critical insight as to the importance of a special receptor on cells called the epidermal growth factor receptor (EGFR). His work and the work of others led to the development of targeted therapies for cells that express EGFR. He explored two approaches to go after the growth receptor. One was the use of monoclonal antibodies – very targeted antibodies – against EGFR. This work could never have been done without the pioneering work of another NFCR Project Director, Nobel Laureate Dr. Cesar Milstein at The MRC Laboratory in Molecular Biology in Cambridge, England.

- **Recently**, NFCR Project Director, Dr. Daniel A. Haber, M.D., Ph.D. at Massachusetts General Hospital, discovered a way to determine which patients would and would not respond to a targeted therapy drug against EGFR. This represents a way to “super-target” patients’ tumors. Dr. Haber demonstrated that only tumors with certain genetic mutations would shrink significantly after being treated with a new EGFR targeting drug, Iressa™. This was truly cutting-edge research, and will help oncologists select patients for specific therapies with greater assurance that the therapies will be effective.
BEATING CANCER: CHARTING NEW FRONTIERS IN TARGETED CANCER THERAPIES

Finally, one of the most exciting new areas of research that has already made a difference for patients with colon, kidney, and lung cancer is the area of angiogenesis (formation of new blood vessels). A great pioneer and NFCR investigator in this area is Dr. Harold Dvorak at the Beth Israel Deaconess Medical Center in Boston. Dr. Dvorak discovered the vascular endothelial growth factor (VEGF) which is critical in inducing tumor blood vessel growth, and the inhibition of VEGF can cut off tumor cells’ blood supply. Antibodies against VEGF are a new type of targeted therapy drug, and are significantly improving the survival of patients with cancer. Most anti-VEGF drugs available today are based on Dr. Dvorak’s NFCR-funded research.

What does all of this mean? It means that the era of targeted, more personalized, more effective, and less toxic cancer therapy is here. NFCR has had great success in accelerating research to this point and will continue funding scientists who are very much dedicated to finding more targets in patients’ tumors and then finding ways to hit those targets to beat cancer.

SPECIAL EVENTS

Volunteers are the backbone of NFCR’s growing outreach efforts. With over 3 million donors nationwide, local volunteers organize events, bring in new donors and most importantly, as individuals all touched by cancer in their own lives, put a face to the need to support cancer research in the laboratory.

U.S. Naval Officer and Homeland Security expert, Kimberly Purlia, contacted NFCR after experiencing cancer in her own family…she wanted to do more. As a result and now in it’s second year, the DC-area Golf for a Cure Classic has raised over $18,000 for NFCR and the event continues to grow. With donations from General Dynamics and similar companies, her passion to find a cure for cancer is certainly making a difference.

In its 8th year, the Pennsylvania Golf Classic in Hazleton, PA continues to be one of our most successful events with donations from all across the Hazleton community. Players for the sellout event include local company executives, cancer survivors and community leaders.

PLANNING TIP

Corporate Matching -

Many companies will match their employees’ and retirees’ giving to charitable causes. Ask your Human Resources Manager if your company matches charitable gifts and it could double or even triple the impact your gifts make on NFCR’s cancer research.
NFCR PARTNERSHIPS

NFCR continues to find new ways to make it easy for individuals to make donations to cancer research. NFCR announced partnership opportunities with the following companies with a portion of the proceeds donated to NFCR cancer research:

**American Airlines** – NFCR is pleased to partner with American Airlines in a dollar-for-miles swap. Every dollar donated to NFCR through this partnership results in 10 AAdvantage® miles. To take advantage of this great offer, visit www.NFCR.org/aadvantage or call 1-800-321-CURE (2873).

**NFCR Flower Club** – NFCR and Teleflora have teamed up to offer flowers and other gifts to NFCR contributors with 20% of the proceeds supporting NFCR. Visit www.nfcr.flowerclub.com or call 1-800-247-1170.

**CancerConsultants** – Specific information about clinical trials and cancer types are critical to those suffering from cancer. NFCR’s partnership with CancerConsultants provides this information free to all NFCR contributors. Our SURVIVE! Newsletters provide the most current and up-to-date cancer information available. To subscribe visit www.NFCR.org.

**ActivHealth** – Managing your health is the first step in preventing cancer! In conjunction with the Duke University Medical Center and the PHD Network, NFCR has partnered with ActivHealth to provide an online resource management tool to help you manage your health, work with top doctors and keep an updated health profile and health assessment online. This tool is available for a small fee and a portion of these proceeds support NFCR cancer research.

CONGRESS RECOGNIZES NFCR’S ROLE IN CANCER RESEARCH

On October 16, 2004, U.S. Congressman Jim Cooper of Tennessee and U.S. Congressman Jim Kolbe of Arizona offered a bi-partisan resolution, HR 403, expressing gratitude for NFCR’s role in providing over $200 million in cancer research and prevention, and bringing hope for millions of cancer patients everywhere.
Dr. Martha Sager is a very special friend to NFCR. In 1973, Dr. Sager joined NFCR's Board of Directors as a founding member, and by doing so, further strengthened her role as an influential player in the field of cancer research. From the outset, her experience as a scientist and educator were an ideal match for a startup organization with big ideas for redefining the approach of cancer research in America.

Over the next 31 years, Dr. Sager's vision and dedication were critical in building NFCR into an organization that meets the needs of scientists and donors alike. She encouraged NFCR to break new ground and to challenge the conventional approaches to cancer research. As a scientist, she valued protocol and the experimental process, but she also recognized that the really big discoveries were achieved by taking risks and trying something new.

This year marked the end of Dr. Sager's tenure on NFCR's board, as she has decided it is time to retire and give others the opportunity to push NFCR to new heights. We will miss her leadership on our board, but will thankfully keep her as a close friend and advisor.

In honor of Dr. Sager's exemplary service to our organization, NFCR's Board of Directors has honored her by creating the Martha C. Sager Rose Fund. This fund is a permanent tribute to her influence on NFCR and the cancer community, and will also serve to continue her vision of funding innovative science. Board members, NFCR staff, friends and family, as well as Dr. Sager herself, have contributed to this fund and will continue to do so for years to come.

Through the creation of a Rose Fund, we thank Dr. Sager for her years of friendship and for her continuing support.

WHAT IS A ROSE FUND?

In September 2004, NFCR launched an innovative new program called NFCR Rose Funds. The program was created based on feedback from NFCR friends and supporters who indicated they wanted a meaningful and personalized way to support cancer research and pay tribute to special people in their lives.

NFCR heard your voices and designed our Rose Funds program to do just that. A Rose Fund enables family, friends and colleagues to support cancer research in honor or memory of someone important to them. First, a named fund is created (for instance, The Martha Sager Rose Fund, or The Miller Family Rose Fund) and then family and friends can raise money to support NFCR's cancer research through the Rose Fund on an ongoing basis.

NFCR can help you notify others about a new Rose Fund and donors can give periodically, sign up for automated monthly donations, or even arrange special events to help grow the fund. NFCR treats Rose Fund contributions as unrestricted gifts unless otherwise specified by the fund organizer.

HOW CAN I SET UP A ROSE FUND?

If creating a Rose Fund interests you, please call Ann Mariani at 1-800-321-2873 and she can answer your questions and mail you an information kit. If you prefer email, the address is Rosefunds@nfcr.org

PLANNING TIPS

Donate Stocks – If you're planning to make a gift to NFCR, consider donating appreciated stocks. You will save yourself the capital gains taxes and receive a larger charitable tax deduction.

Gain by Giving – A charitable gift annuity can provide you with a guaranteed lifetime income (partially tax-free) and an immediate tax deduction. Best of all, your gift will help accelerate NFCR's cancer research programs so we can save more lives.
To succeed in finding a cure for cancer, NFCR recognizes that planning and choosing the right strategies are crucial. We must make sure that we invest our research dollars wisely so we can make the biggest impact in the shortest amount of time.

NFCR relies heavily on the support of caring individuals to fund our research initiatives. In order to plan our attack against cancer, it is critical that we have the means available to fund new and innovative research opportunities.

The easiest way to contribute to NFCR's cancer research programs is to give a gift of cash. You can mail a contribution or make a donation online at www.NFCR.org. NFCR gladly accepts personal checks and most major credit cards. If you would like to make your gift in Honor or Memory of someone, we’d be happy to tell you how.

Depending on your philanthropic goals and financial situation, certain types of gifts may be better for you. NFCR can offer several suggestions about creative giving options such as:

- Gifts that guarantee lifetime payments you can never outlive
- Gifts that offer significant tax savings
- Wills and Bequests to leave a lasting legacy
- Gifts of land in return for payments for life
- Gifts you can live in
- Gifts to take care of loved ones
- Grants from Family Foundations

If you would like to consider ways to help defeat cancer, please call 1-800-321-CURE (2873) and ask to speak to one of our planned giving officers. We’re happy to help!

Taking the Next Step:

To find out more about the following types of gifts, please call us at 1-800-321-CURE (2873):

- Charitable Gift Annuities
- Wills and Bequests
- Real Estate
- Foundation Grants
- Appreciated Securities
- Charitable Remainder Trusts
- Charitable Lead Trusts
- Life Insurance
- Retirement Account Beneficiary Gifts
- Employee Matching

NFCR is committed to the highest standards of accountability to our donors, friends and scientists. We meet the standards of the Better Business Bureau’s Wise Giving Alliance and our stewardship of your donations ensures that over 73% of every dollar goes directly to cancer research and prevention.
INDEPENDENT AUDITORS' REPORT

Board of Directors
National Foundation for Cancer Research, Inc.:

We have audited the accompanying consolidated statements of financial position of the National Foundation for Cancer Research, Inc. and affiliates (the Foundation) as of September 30, 2004, and the related consolidated statements of activities and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Foundation's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. The prior year summarized comparative information has been derived from the Foundation's 2003 financial statements, and in our report dated January 13, 2004, we expressed an unqualified opinion on those financial statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the National Foundation for Cancer Research, Inc. and affiliates at September 30, 2004, and their changes in net assets and their cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

Our audit was conducted for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplementary information included in the consolidated schedule of functional expenses is presented for purposes of additional analysis and is not a required part of the basic financial statements. Such information has been subjected to the auditing procedures applied in the audit of the basic financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

KPMG LLP

December 10, 2004
### NATIONAL FOUNDATION FOR CANCER RESEARCH, INC.

#### Consolidated Statements of Financial Position
September 30, 2004 and 2003

<table>
<thead>
<tr>
<th>Assets</th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$949,580</td>
<td>553,652</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>380,967</td>
<td>244,974</td>
</tr>
<tr>
<td>Bequests receivable (note 2c)</td>
<td>716,969</td>
<td>729,416</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>238,376</td>
<td>318,311</td>
</tr>
<tr>
<td>Furniture and equipment, net of accumulated depreciation (note 3)</td>
<td>265,659</td>
<td>221,307</td>
</tr>
<tr>
<td>Investments (note 4)</td>
<td>7,609,735</td>
<td>6,721,973</td>
</tr>
<tr>
<td>Amounts held in trust by others (note 5)</td>
<td>1,669,130</td>
<td>1,605,173</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$11,850,436</strong></td>
<td><strong>10,395,206</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Net Assets</th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and other liabilities</td>
<td>$1,019,291</td>
<td>634,000</td>
</tr>
<tr>
<td>Research contracts payable (note 7)</td>
<td>692,226</td>
<td>117,915</td>
</tr>
<tr>
<td>Accrued compensation and benefits</td>
<td>222,172</td>
<td>64,691</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>2,206</td>
<td>42,250</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>1,935,895</strong></td>
<td><strong>858,856</strong></td>
</tr>
<tr>
<td>Net assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Designated for research (note 7)</td>
<td>5,314,894</td>
<td>4,582,912</td>
</tr>
<tr>
<td>Undesignated</td>
<td>2,055,481</td>
<td>2,331,476</td>
</tr>
<tr>
<td>Temporarily restricted (note 6)</td>
<td>7,370,375</td>
<td>7,114,388</td>
</tr>
<tr>
<td>Permanently restricted (note 6)</td>
<td>1,105,816</td>
<td>1,037,984</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>$11,850,436</strong></td>
<td><strong>10,395,206</strong></td>
</tr>
</tbody>
</table>

*See accompanying notes to consolidated financial statements.*

### NATIONAL FOUNDATION FOR CANCER RESEARCH, INC.

#### Consolidated Statement of Activities
Year ended September 30, 2004 (with comparative totals for 2003)

<table>
<thead>
<tr>
<th>Revenues, gains, and other support:</th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public support</td>
<td>$11,534,643</td>
<td>133,246</td>
</tr>
<tr>
<td>Bequests</td>
<td>1,545,596</td>
<td>1,545,596</td>
</tr>
<tr>
<td>Noncash support (note 8)</td>
<td>1,547,064</td>
<td>1,547,064</td>
</tr>
<tr>
<td>Mailing list rentals</td>
<td>611,502</td>
<td>611,502</td>
</tr>
<tr>
<td>Net investment gain (note 4)</td>
<td>638,479</td>
<td>638,479</td>
</tr>
<tr>
<td>Change in value of split-interest agreements</td>
<td>(9,660)</td>
<td>9,586</td>
</tr>
<tr>
<td>Other revenue</td>
<td>46,681</td>
<td>46,681</td>
</tr>
<tr>
<td><strong>Total revenues, gains, and other support</strong></td>
<td>15,989,305</td>
<td>67,832</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses (note 10):</th>
<th>2004</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services:</td>
<td></td>
</tr>
<tr>
<td>Research (notes 7 and 8)</td>
<td>5,976,710</td>
</tr>
<tr>
<td>Public education and information</td>
<td>5,446,279</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td>11,422,989</td>
</tr>
<tr>
<td>Supporting services:</td>
<td></td>
</tr>
<tr>
<td>Fund-raising</td>
<td>3,645,420</td>
</tr>
<tr>
<td>Management and general</td>
<td>664,909</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td>4,310,329</td>
</tr>
<tr>
<td>Total expenses</td>
<td>15,733,318</td>
</tr>
<tr>
<td>Change in net assets</td>
<td>253,987</td>
</tr>
</tbody>
</table>

| Net assets, beginning of year | 7,114,388 | 1,383,978 | 9,536,350 | 7,800,157 |
| Net assets, end of year | $7,370,375 | 1,105,816 | 1,438,350 | 9,536,350 |

*See accompanying notes to consolidated financial statements.*
# Consolidated Statements of Cash Flows

## Years ended September 30, 2004 and 2003

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$378,191</td>
<td>1,736,193</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>61,204</td>
<td>67,389</td>
</tr>
<tr>
<td>Net (gain) loss on investments</td>
<td>(358,901)</td>
<td>(336,296)</td>
</tr>
<tr>
<td>Contribution of furniture</td>
<td>(40,333)</td>
<td>—</td>
</tr>
<tr>
<td><strong>Increase) Decrease in assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>(135,993)</td>
<td>177,571</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>12,447</td>
<td>(546,610)</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>60,135</td>
<td>(182,160)</td>
</tr>
<tr>
<td>Advances to researchers</td>
<td>—</td>
<td>322,500</td>
</tr>
<tr>
<td>Amounts held in trust by others</td>
<td>(63,957)</td>
<td>(121,353)</td>
</tr>
<tr>
<td><strong>Increase (decrease) in liabilities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and other liabilities</td>
<td>385,291</td>
<td>371,685</td>
</tr>
<tr>
<td>Research contracts payable</td>
<td>574,311</td>
<td>(109,890)</td>
</tr>
<tr>
<td>Accrued compensation and benefits</td>
<td>157,481</td>
<td>10,832</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(40,044)</td>
<td>32,660</td>
</tr>
<tr>
<td><strong>Net cash provided by operating activities</strong></td>
<td>$989,832</td>
<td>1,422,521</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from investing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase of investments</td>
<td>(6,231,091)</td>
<td>(11,572,996)</td>
</tr>
<tr>
<td>Proceeds from sale or maturities of investments</td>
<td>5,702,210</td>
<td>10,141,716</td>
</tr>
<tr>
<td>Purchase of fixed assets</td>
<td>(65,023)</td>
<td>(71,125)</td>
</tr>
<tr>
<td><strong>Net cash (used) in investing activities</strong></td>
<td>(593,904)</td>
<td>(1,502,405)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net increase (decrease) in cash</strong></td>
<td>395,928</td>
<td>(79,884)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash and cash equivalents, beginning of year</strong></td>
<td>553,652</td>
<td>633,336</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash and cash equivalents, end of year</strong></td>
<td>$949,580</td>
<td>553,652</td>
</tr>
</tbody>
</table>

*See accompanying notes to consolidated financial statements.*
## National Foundation for Cancer Research, Inc.

### Consolidated Schedule of Functional Expenses

Year ended September 30, 2004 (with comparative totals for 2003)

<table>
<thead>
<tr>
<th>Description</th>
<th>Public education and information</th>
<th>Fund-raising</th>
<th>Management and general</th>
<th>Total 2004</th>
<th>Total 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounting and audit fees</td>
<td>$ —</td>
<td>—</td>
<td>—</td>
<td>62,530</td>
<td>46,637</td>
</tr>
<tr>
<td>Bank and payroll service fees</td>
<td>—</td>
<td>55,016</td>
<td>—</td>
<td>55,016</td>
<td>46,622</td>
</tr>
<tr>
<td>Conferences</td>
<td>111,606</td>
<td>111,606</td>
<td>—</td>
<td>66,905</td>
<td>47,607</td>
</tr>
<tr>
<td>Creative fees</td>
<td>—</td>
<td>23,243</td>
<td>47,034</td>
<td>23,243</td>
<td>47,034</td>
</tr>
<tr>
<td>Data services</td>
<td>20,243</td>
<td>342,621</td>
<td>18,438</td>
<td>342,621</td>
<td>792,003</td>
</tr>
<tr>
<td>Depreciation</td>
<td>16,533</td>
<td>8,804</td>
<td>7,330</td>
<td>32,677</td>
<td>50,658</td>
</tr>
<tr>
<td>Dues, subscriptions and professional development</td>
<td>4,614</td>
<td>3,932</td>
<td>48,735</td>
<td>57,281</td>
<td>38,709</td>
</tr>
<tr>
<td>Fund for inherited disease research</td>
<td>881,684</td>
<td>—</td>
<td>10,119</td>
<td>881,684</td>
<td>934,454</td>
</tr>
<tr>
<td>Insurance - business</td>
<td>4,182</td>
<td>10,119</td>
<td>25,146</td>
<td>35,251</td>
<td>25,541</td>
</tr>
<tr>
<td>Investment fees</td>
<td>—</td>
<td>43,713</td>
<td>43,713</td>
<td>43,713</td>
<td>32,116</td>
</tr>
<tr>
<td>Legal fees and expenses</td>
<td>14,527</td>
<td>1,895</td>
<td>39,696</td>
<td>56,916</td>
<td>61,337</td>
</tr>
<tr>
<td>Licenses and permits</td>
<td>—</td>
<td>—</td>
<td>11,917</td>
<td>11,917</td>
<td>12,492</td>
</tr>
<tr>
<td>List processing fee</td>
<td>—</td>
<td>40,098</td>
<td>—</td>
<td>40,098</td>
<td>100,616</td>
</tr>
<tr>
<td>List rental</td>
<td>371,557</td>
<td>—</td>
<td>250,267</td>
<td>301,824</td>
<td>433,170</td>
</tr>
<tr>
<td>Lockbox and data entry</td>
<td>131,371</td>
<td>90,085</td>
<td>221,456</td>
<td>221,456</td>
<td>200,256</td>
</tr>
<tr>
<td>Mailshop fees</td>
<td>380,622</td>
<td>242,300</td>
<td>622,922</td>
<td>622,922</td>
<td>433,828</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>320</td>
<td>9,088</td>
<td>22,360</td>
<td>23,269</td>
<td>8,727</td>
</tr>
<tr>
<td>Noncash research support</td>
<td>1,506,731</td>
<td>—</td>
<td>1,506,731</td>
<td>1,506,731</td>
<td>2,327,837</td>
</tr>
<tr>
<td>Occupancy</td>
<td>68,994</td>
<td>19,936</td>
<td>145,933</td>
<td>145,933</td>
<td>128,422</td>
</tr>
<tr>
<td>Office supplies and expenses</td>
<td>17,463</td>
<td>1,756</td>
<td>33,878</td>
<td>33,878</td>
<td>32,538</td>
</tr>
<tr>
<td>Peer review meetings and expenses</td>
<td>—</td>
<td>—</td>
<td>15,671</td>
<td>15,671</td>
<td>15,671</td>
</tr>
<tr>
<td>Personnel</td>
<td>729,070</td>
<td>223,380</td>
<td>1,619,617</td>
<td>1,619,617</td>
<td>1,366,989</td>
</tr>
<tr>
<td>Postage</td>
<td>1,93,194</td>
<td>6,945</td>
<td>3,025,511</td>
<td>3,025,511</td>
<td>2,858,161</td>
</tr>
<tr>
<td>Printing and publication</td>
<td>1,283,747</td>
<td>24</td>
<td>2,515,728</td>
<td>2,515,728</td>
<td>2,222,974</td>
</tr>
<tr>
<td>Production fees</td>
<td>20,429</td>
<td>17,710</td>
<td>38,139</td>
<td>38,139</td>
<td>59,266</td>
</tr>
<tr>
<td>Professional fees and expenses</td>
<td>1,283,747</td>
<td>24</td>
<td>2,515,728</td>
<td>2,515,728</td>
<td>2,222,974</td>
</tr>
<tr>
<td>Public education materials and Web-site</td>
<td>57,753</td>
<td>120</td>
<td>60,050</td>
<td>60,050</td>
<td>183,177</td>
</tr>
<tr>
<td>Research contracts and grants</td>
<td>2,469,747</td>
<td>—</td>
<td>2,469,747</td>
<td>2,469,747</td>
<td>2,335,825</td>
</tr>
<tr>
<td>Telephone services</td>
<td>6,672</td>
<td>2,338</td>
<td>14,394</td>
<td>14,394</td>
<td>19,276</td>
</tr>
<tr>
<td>Travel and business meetings</td>
<td>52,397</td>
<td>37,129</td>
<td>93,431</td>
<td>93,431</td>
<td>52,742</td>
</tr>
</tbody>
</table>

$ 5,976,710 $ 5,446,279 $ 3,645,420 $ 664,909 $ 15,733,318 $ 15,181,618

See accompanying independent auditors’ report.

### Notes to Consolidated Financial Statements

#### September 30, 2004 and 2003

**1) The Organization**

The National Foundation for Cancer Research, Inc. (the Foundation) was incorporated in Massachusetts in 1973 “to support basic science cancer research projects including the theories of Dr. Albert Szent-Gyorgyi who discovered Vitamin C.” The purposes of the Foundation are to conduct basic science cancer research and to provide educational information about cancer to the public. The Foundation has provided services and operated under the names Cancer Research Laboratories Foundation, Inc. and Cancer Research Coalition. Both of these entities were inactive during the years ended September 30, 2004 and 2003.

Fund for Inherited Disease Research, Inc. (FIDR) was incorporated in October 2000 as a tax-exempt supporting organization to the Foundation. FIDR is devoted to furthering scientific research related to Von Willebrand’s Disease, a life-threatening genetic abnormality which affects females, particularly adolescents. FIDR activities have been consolidated with those of the Foundation for the years ended
September 30, 2004 and 2003. All significant intercompany transactions and accounts have been eliminated.

(2) Summary of Significant Accounting Policies

The financial statements of the Foundation have been prepared on the accrual basis of accounting.

(a) Basis of Presentation

Net assets and revenues, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, the net assets of the Foundation and changes therein are classified and reported as follows:

*Unrestricted net assets* – Net assets that are not subject to donor-imposed stipulations.

*Temporarily restricted net assets* – Net assets subject to donor-imposed stipulations that may or will be met either by actions of the Foundation and/or the passage of time.

*Permanently restricted net assets* – Net assets subject to donor-imposed stipulations that they be maintained permanently by the Foundation.

Revenues are reported as increases in unrestricted net assets unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in unrestricted net assets. Gains and losses on investments are reported as increases or decreases in unrestricted net assets unless their use is restricted by explicit donor stipulation or by law. Expirations of temporary restrictions on net assets (i.e., donor-stipulated purpose has been fulfilled and/or stipulated time period has elapsed) are reported as reclassifications between the applicable classes of net assets.

(b) Contributions

Public support is recorded as revenue when contributions, which include unconditional promises to give (pledges), are received. The Foundation has adopted a policy of recording donor-restricted contributions as unrestricted revenue when the restrictions are met in the same reporting period as the gift is received.

(c) Bequests

The Foundation is the beneficiary under various wills and trust agreements. The Foundation records such amounts when notified that the amounts have cleared probate.

(d) Cash and Cash Equivalents

Cash equivalents include amounts invested in an overnight sweep account.

(e) Prepaid Expenses

Prepaid expenses generally include unused postage purchased prior to September 30, insurance, and rent.

(f) Furniture and Equipment

Expenditures for furniture and equipment are capitalized at cost using a capitalization threshold of $500. Furniture and equipment are depreciated on the straight-line basis over the estimated useful lives of the assets of 5 to 10 years.

Leasehold improvements are capitalized at cost and amortized on the straight-line basis over the remaining life of the lease.

(g) Investments

Investments, which are recorded at fair value, consist of corporate stocks and bonds, government securities with maturities greater than 90 days, money market funds, and certificates of deposit.

(h) Functional Allocation of Expenses

The costs of providing the Foundation's programs and services are summarized on a functional basis in the accompanying financial statements. Accordingly, certain costs have been allocated between the programs and services benefited (see note 10).
(i) Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The Foundation is also required to make estimates and assumptions that affect reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates.

(j) Income Taxes
The Foundation is generally exempt from federal income tax under Internal Revenue Code Section 501(c)(3), except on unrelated business income, if any. It qualifies as a public charity under Section 509(a). FIDR is generally exempt from federal income tax under Section 501(c)(3), except for unrelated business income, if any. It is a public charity under Section 509(a)(3).

(3) Furniture and Equipment
Furniture and equipment at September 30, 2004 and 2003 consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computer equipment and software</td>
<td>$209,962</td>
<td>169,972</td>
</tr>
<tr>
<td>Office furniture and equipment</td>
<td>332,916</td>
<td>263,547</td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>23,917</td>
<td>23,917</td>
</tr>
<tr>
<td></td>
<td>562,795</td>
<td>457,436</td>
</tr>
<tr>
<td>Less accumulated depreciation</td>
<td>(297,136)</td>
<td>(235,929)</td>
</tr>
<tr>
<td></td>
<td>$265,659</td>
<td>221,507</td>
</tr>
</tbody>
</table>

(4) Investments
Investments at September 30, 2004 and 2003 consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds</td>
<td>$292,968</td>
<td>398,600</td>
</tr>
<tr>
<td>Certificates of deposit</td>
<td>1,500,000</td>
<td>1,900,000</td>
</tr>
<tr>
<td>Corporate bonds</td>
<td>1,554,142</td>
<td>1,064,236</td>
</tr>
<tr>
<td>U.S. government and agency securities</td>
<td>1,489,310</td>
<td>1,468,596</td>
</tr>
<tr>
<td>Common and preferred stocks</td>
<td>2,773,335</td>
<td>1,890,541</td>
</tr>
<tr>
<td></td>
<td>$7,609,755</td>
<td>6,721,973</td>
</tr>
</tbody>
</table>

Net investment gain for the years ended September 30, 2004 and 2003 consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest and dividend income</td>
<td>$279,578</td>
<td>252,639</td>
</tr>
<tr>
<td>Net gain on investments</td>
<td>358,901</td>
<td>336,296</td>
</tr>
<tr>
<td></td>
<td>$638,479</td>
<td>588,935</td>
</tr>
</tbody>
</table>

Foundation investments are managed by Wachovia Securities, Mercantile-Safe Deposit & Trust Company, M&T Bank, and Merrill Lynch. Money market funds are classified as investments because they are held for investment purposes.

(5) Amounts Held in Trust by Others
The Foundation is the beneficiary of several split-interest agreements, including irrevocable perpetual trusts and charitable remainder trusts, as described in Internal Revenue Code Section 664. The Foundation does not exercise control over the trusts’ assets, which are held and administered by third-party trustees.
Under the perpetual trusts, the donors established and funded a trust whereby the Foundation is the beneficiary of the income on the trust assets as earned in perpetuity with no restrictions on use. Under the charitable remainder trusts, the donors established and funded a trust whereby the Foundation receives income distributions from the trust and will receive a percentage of trust assets at the termination of the trust.

The perpetual trusts are stated at the fair value of the assets of the trust. Fair value at September 30, 2004 and 2003 was $1,418,350 and $1,363,980, respectively. The change in the beneficial interest in perpetual trusts for the years ended September 30, 2004 and 2003 was $54,372 and $108,454, respectively.

The Foundation’s interest in charitable remainder trusts is stated at fair value, representing the estimated amount to be received at the termination of the trusts. The amount recorded at September 30, 2004 and 2003 was $250,780 and $241,193, respectively.

(6) Net Assets

Temporarily restricted net assets balances at September 30, 2004 and 2003 of $1,105,816 and $1,037,984, respectively, consist of split-interest agreements held by the Foundation, net assets of FIDR consisting of contributions restricted for certain types of cancer research, and other miscellaneous contributions restricted for specific types of cancer research.

Temporarily restricted net assets released from restriction for the years ended September 30, 2004 and 2003 related to contributions spent for specific types of cancer research.

Permanently restricted net assets consist of perpetual trusts and endowments for which the Foundation is named as a beneficiary. Investment income realized on the permanently restricted net assets balance of $1,438,350 and $1,383,978 as of September 30, 2004 and 2003, respectively, is unrestricted for use by the Foundation.

(7) Research Contracts

The Foundation enters into agreements with universities and other institutions to conduct scientific research on their premises, in accordance with policies established by the governing board of the Foundation. Research contracts payable represents research expenses incurred during the year under these contracts, but not yet paid to the institutions as of year-end. At September 30, 2004 and 2003 research contracts payable amounted to $692,226 and $117,915, respectively.

At September 30, 2004 and 2003, the board of directors has designated unrestricted net assets in order to fulfill contract commitments to universities and institutions for research amounting to $5,314,894 and $4,582,912, respectively.

(8) Noncash Support

University Support
Research contracts with universities and other institutions typically reimburse most out-of-pocket research costs; however, many institutions also agree to donate certain chemicals, materials, equipment, databases, and supercomputer time. These donations, provided by the institutions, become a normal part of the research program and would ordinarily be costs incurred by the Foundation.

Control over these donated goods is provided through on-location project directors, who are responsible to the Foundation for the research projects at the institutions.

The effect of these donations is to allow the Foundation to expand the research that would otherwise be performed under the contract. The institutions provide the Foundation with
a measurable basis in order to quantify the estimated fair value of the donated property.

For the years ended September 30, 2004 and 2003, noncash support consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>University support</td>
<td>$ 1,506,731</td>
<td>$ 1,401,518</td>
</tr>
<tr>
<td>Screen Saver Project</td>
<td>—</td>
<td>900,000</td>
</tr>
<tr>
<td>New Frontier in Nucleic Acids</td>
<td>—</td>
<td>26,319</td>
</tr>
<tr>
<td>Research Berlin Conference</td>
<td>40,333</td>
<td>—</td>
</tr>
<tr>
<td>Furniture donation</td>
<td>40,333</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$ 1,547,064</td>
<td>$ 2,327,837</td>
</tr>
</tbody>
</table>

(9) Retirement Plan

The Foundation has a defined contribution money purchase plan which covers all full-time employees with at least 1,000 hours of annual service. The Foundation contributes an amount equal to 12% of the participating employees’ eligible salaries to the plan each year. For the years ended September 30, 2004 and 2003, retirement expense was approximately $105,000 and $115,000, respectively.

(10) Allocation of Joint Costs

For the years ended September 30, 2004 and 2003, the Foundation incurred joint costs of approximately $8,174,000 and $7,328,000, respectively, for informational materials and activities that included fund-raising appeals, which were allocated as follows:

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$ 1,000</td>
<td>52,000</td>
</tr>
<tr>
<td>Fund-raising</td>
<td>3,255,000</td>
<td>3,233,000</td>
</tr>
<tr>
<td>Public education</td>
<td>4,911,000</td>
<td>4,030,000</td>
</tr>
<tr>
<td>and information</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>7,000</td>
<td>13,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$ 8,174,000</td>
<td>7,328,000</td>
</tr>
</tbody>
</table>

(11) Lease Commitments

The Foundation and affiliates lease office space under a non-cancelable operating lease. Future minimum lease payments under the operating lease as of September 30, 2004 are as follows:

<table>
<thead>
<tr>
<th>Year ending September 30:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>$ 188,779</td>
</tr>
<tr>
<td>2006</td>
<td>181,093</td>
</tr>
<tr>
<td>2007</td>
<td>186,507</td>
</tr>
<tr>
<td>2008</td>
<td>192,087</td>
</tr>
<tr>
<td>2009</td>
<td>197,835</td>
</tr>
<tr>
<td>Thereafter</td>
<td>377,798</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$ 1,324,099</td>
</tr>
</tbody>
</table>

Rent expense for the years ended September 30, 2004 and 2003 was $145,933 and $128,422, respectively.
Believing in the value of innovative ideas, NFCR is committed to supporting discovery-oriented research of proven scientists. Receiving no government funding, support from caring individuals like you is the primary means by which we enable our scientists to make significant breakthroughs in the war against cancer. Through an efficient organizational infrastructure, NFCR has provided many scientists with the “seed” money to explore and discover uncharted territories, and to bring these findings from laboratories to the bedside of cancer patients. Over the past 30-plus years we have spent over $210 million to support innovative basic science cancer research and cancer prevention.

In fiscal year 2004, as always, NFCR and our scientists are immensely grateful to all our friends who have joined us in the fight against cancer. We extend our special appreciation to members who have generously contributed $1000.00 or more. With your dedication and our determination, we will find a cure for cancer. NFCR is Research for a Cure.

ACKNOWLEDGEMENT OF CONTRIBUTORS

**Estates & Trusts**

- Estate of Albert B. Bauer
- Estate of Ada Vaughn Bierly
- Estate of Harvey Bogen
- Estate of Elizabeth H. Bouland
- Estate of Julia Colvin Clark
- Estate of Mildred Clemente
- Estate of Ray Coady
- Estate of Wilma E. Coates
- Estate of Mary Frances Colvin
- Estate of Eva Lore Corton
- Estate of Genovefa Curtis
- Estate of Ardis E. Doyle
- Estate of Emma L. Erickson
- Estate of Louis Fink
- Estate of Veronica Gnip
- Estate of Eleanor L. Hart
- Estate of Carl O. Hensher
- Estate of Shirley L. Johnson
- Estate of Elmer Leffingwell
- Estate of DeNard B. Kirk
- Estate of Claire T. Mellman
- Estate of Stephanie Miller
- Estate of Mary E. O’Neil
- Estate of Ethel A. Pierson
- Estate of Nancy B. Price
- Estate of Beulah G. Ramsey
- Estate of Benton Rogers
- Estate of Minna Rykart
- Estate of Marjorie Schoch
- Estate of Margaret A. Schwartz
- Estate of Frederika Steiner
- Estate of Elizabeth Jane Stephenson
- Estate of Dora Tobias
- Estate of Joan S. Waldron
- Estate of Marcia Zabriskie
- Trust of Anonymous
- Trust of Geneva Armil
- Trust of Robert T. Aramil
- Trust of Beth & Preston Belcher
- Trust of James Childs
- Trust of Mary D. Embree
- Trust of Grace W. Densmore
- Trust of Gertrude F. Dickson
- Trust of Mildred R. Dumbauld
- Trust of Stephen V. Good
- Trust of Wilbur C. Grosse
- Trust of Marjorie Hahn
- Trust of Arthur & Hannah Heymann
- Trust of John T. Holowiak
- Trust of Leonard and Eustelle Hudson
- Trust of Elsie A. King
- Trust of Judith Anne Lee
- Trust of Edward Low
- Trust of Susan Mahn
- Trust of Ingrid Palmgren
- Trust of William C. Reed
- Trust of Albert & Eleanor Repecka
- Trust of Pauline Rucker
- Trust of Shirley Schlessinger
- Trust of Ruth S. Shapiro
- Trust of Grace E. Spelman
- Trust of Mabel Taylor
- Trust of Juanita Whitt Whear
- Trust of Florence K. Yeager

**Individuals**

- Dr. Amina R. Allaudin
- Dr. Walter E. App
- Mr. Michael F. G. Ashby
- Dr. Sujuan Ba
- Mr. & Mrs. Donald J. Barnes
- Mrs. Thomas Basis
- Ms. Peggy Ann Bishop
- Ms. Bonnie Blandford
- Ms. Helen C. Bones
- Mr. & Mrs. Donald Brezlin
- David & Carol Buckel
- Mr. Henry Buttery
- Mr. Steve Callas
- Mackenzie Canter, Esq.
- Mrs. Alice Catalyne
- Miss Lila M. Chaliss
- Mr. Alfred Chamizo
- Mr. Glen Charles
- Mrs. Audrey H. Charlson
- Mrs. Alice B. Clark
- Bruce & Wilma Classon
- Mr. Kevin A. Connolly
- Ms. Carol L. Cook
- Mr. Dennis M. Cooke
- Mr. David Y. Cooper
- Ms. Diana Corson
- Ms. Judith M. Coulter
- Mr. Kevin Craun
- Mr. Edward Cukrowicz
- Dr. Bethia S. Currie
- Ms. Joyce E. Dakis
- Ms. Pauline K. Dall
- Mr. Byron G. Davis
- Mr. Foster De Reitzes
- Dr. Joseph De Rose
- Mr. Billy Denizard
- Mr. & Mrs. Joseph M. Desalas
- Thomas & Jennifer Dudley
- Ms. Catherine W. Dukehart
- Mr. Mike Duncan
- Ms. Christine Dunekack
- Mr. James M. Dunstan
- Mrs. Wenqi Dwyer
- Mrs. Betty A. Eberle
- Empire State Carpenters
- Mr. Richard D. Ennen
- Mr. & Mrs. Edward R. Evans
- Mr. & Mrs. Jeffrey Fang
- Mr. Alejandro Fernandez
Private Foundations and Corporations

NFCR would like to recognize the following private foundations and corporations for their generous support of NFCR’s research and public education programs during the 2004 Fiscal Year.

Alabama
- The Jurenko Foundation

Arizona
- Susan and Ford Schumann Foundation
- Nevai Charitable Foundation

California
- Auer Family Foundation
- The Bellini Foundation
- Max & Judy Brown Fund of the Jewish Community Foundation
- Estelle Funk Foundation
- Burt & Diana Cutler Family Foundation
- The David E. Gallo Foundation
- The Hanna Foundation
- The Hornthal Family Foundation
- Louis & Clara Kennedy Family Foundation
- Millard & Muriel Jacobs Family Foundation
- Louis & Jane Jacobson Family Foundation
- Leo & Gertrude Marantz Fund
- Curt & Gerry Pindler Foundation
- The Marion Rose Foundation
- David & Carole Schultz Family Foundation
- David Schwartz Foundation
- Surfside Funding Corporation
- Tamkin Foundation
- The David & Diane Toole Foundation
- The Weiss Foundation
- The Wolfe Foundation
- B. Y. Foundation

Colorado
- The Hyman Foundation
- National Foundation for Philanthropy
- Morris & Libby Singer Foundation

Connecticut
- Jewish Community Endowment Foundation
- The Hollander Foundation
- The Moskowitz Foundation
- The Schwedel Foundation
- Andre & Elaine Suan Foundation

Washington, DC
- The Benedictine Foundation
- Maher Charitable Foundation

Corporate Sponsorships

CP Direct
ILEX Oncology, Inc.
Landcraft, Inc.
Merkle Direct Marketing, Inc.
Millenium Pharmaceuticals
Sam’s Club
V6 General Dynamics
SynerGene Therapeutics, Inc.
Florida
Allen Family Foundation
David Altman Foundation
The Avellino Family Foundation
Blue Grass Foundation
Leo J. & Celia Carlin Charitable Foundation
The Alvin & Fern Davis Foundation
Morton & Mildred Davis Family Foundation
The Edwards Foundation
Bella & Seymour Goldberg Foundation
The Gordon Foundation
Greater Miami Jewish Federation
The Artzt Howard Foundation
Huizenga Family Foundation
Kaplan Fund of the Greater Miami Jewish Federation
James & Viola Lane Foundation
Jacqueline & Sherman Lowy Foundation
Diane & James Perrella Family Foundation
Frederick & Greta Smiley Charitable Foundation
The Tyrrell Foundation
The Peter & Anna Vanderveld Foundation
Norman & Vivian Weiden Foundation
Simon & Sylvia Zisman Foundation

Georgia
T. W. Erickson Foundation

Hawaii
Hawaii Community Foundation

Illinois
Coach's Crew Foundation
Cole Family Foundation
Rhoda & Henry Frank Family Foundation
Jack Jennings Foundation Trust
Kapoor Charitable Foundation
Robinson Charitable Foundation
Seiden Family Foundation
Samuel Weinstein Family Foundation
Robert T. Williams Fund

Indiana
Kroot Family Foundation

Kansas
Jana E Pinker Memorial Foundation

Kentucky
Community Foundation of Louisville

Massachusetts
The Corrigan Foundation

Maryland
Balle Family Foundation
Gertrude & Israel Freedman Foundation
Lowell & Harriet Glazer Family Foundation
Mary & Christopher Rodgers Foundation
Carolyn & Lawrence Silverman Family Foundation
David B. & Shirley L. Sykes Foundation

Michigan
Stanley & Blanche Ash Foundation
Broomfield Charitable Foundation
Samuel & Jean Frankel Foundation
Robert & Sharon Grooters Foundation
The Siebenthaler Foundation

Minnesota
Chapel Fund - Saint Cloud Hospital
Arthur & Constance Goodman Family Foundation
The Lamm Family Foundation

Missouri
Argo Foundation
Samuel Honigberg Foundation

Nevada
Paws Up Foundation
Colette & Sidney Saltz Foundation

New Hampshire
Watts Family Foundation

Nebraska
Maurice Feldman Family Foundation

New Jersey
Cookie Jar Foundation
The Margaret A. Darrin Foundation
Allegra & Isaac Franco Foundation
Hopewell Hospice Foundation of America
Litterman Family Foundation
The Manealoff Foundation
Montery Fund
Benjamin & Mildred Rosenzweig Foundation
The SAD Foundation
The Darla Dee Turlington Charitable Foundation

New York
The Murray Alon Charitable Foundation
Americans We Are a Family Foundation
Doreen & Gilbert Bassin Family Foundation
The Rachel & Isaac Bukstein Foundation
The Cavallo Family Foundation
The Marilyn & Stanley Cohen Foundation
Harry & Misook Doolittle Foundation
The Fein Foundation
The Feuerring Foundation
Sol & Hilda Furst Foundation
Bernard & Florence Galkin Foundation
Gifford-Rudin Foundation
Benjamin Gittlin Foundation
Stanley F. Goldfein Foundation
Shirley W. & William L. Griffin Foundation
A. S. Guterman Foundation
Edward Handelman Fund
David Heckler Foundation
Simon & Marie Jaglom Foundation
The Kandell Fund
Kittay Foundation
The Krupman Family Foundation
The M. J. & Carol G. Lebworth Foundation
The Mortimer Levitt Foundation
Luntz Family Foundation
The Elena Melius Foundation
Benjamin W. & Marian B. Roth Foundation
The Norman & Constance Sadek Foundation
Schon Family Foundation
The James H. & Margaret Tabeling Foundation
The Victor & Pearl Tumpeper Foundation
Ullman Foundation
Sam & Gerry Ward Foundation
Elias & Harriet M. Wollerstein Foundation

North Carolina
Community Foundation of Western North Carolina
Grover & Jane McNair Charitable Foundation
Wiegand Family Foundation

Ohio
R. Gordon & Agnes K. Black Family Foundation
DeHayes Foundation
Barbara Quint Levy Philanthropic Fund
Ronald & Shirley Parson Fund
Tecca Foundation

Oklahoma
H. O. W. Foundation of Oklahoma

Pennsylvania
Foster Foundation
Harvey Rosalie Goldberg Private Foundation
Matzkin Foundation
Mario & Sara Rafalin Foundation
Harry Stern Family foundation
A. H. & Helen L. Weiss Foundation

Puerto Rico
FNZ Foundation
Corporate Matching

NFCR would also like to recognize the following organizations that have generously supported the NFCR Employee Matching Gifts Program during the 2004 Fiscal Year.

Arkansas
4Charity Foundation

California
Amen Foundation
The California Wellness Foundation
The Capital Group Companies
The Fieldstone Foundation
The J. Paul Getty Trust
Kawasaki Motors Corporation
Qualcomm
Symantec Corporation
Universal Music Group

Colorado
Ball Corporation
Duke Energy Field Services
Oppenheimer Funds
Whiting Petroleum

Connecticut
The Stanley Works
XTRA Corporation Charitable Foundation

Washington, DC
GEICO Direct

Florida
Fannie Mae Foundation

Georgia
Equifax

Iowa
Maytag Corporation Foundation
Pella Rolscreen Foundation

Illinois
Aon Foundation
CNA Foundation
Harris Bank Foundation
Square D Foundation
United Airlines

Indiana
Indianapolis Power and Light Company

Kansas
Aventis Pharmaceutical

Massachusetts
The Millipore Foundation

Maryland
T. Rowe Price Associates Foundation

Minnesota
ADC Foundation
Highland Banks

Missouri
Mallinkrodt

New Hampshire
Eastern Mountain Sports

New Jersey
3Com Corporation
AMD
Adobe Systems
Altria
American Ref-Fuel Company
BD (Becton Dickinson & Company)
BP Foundation
Charles Schwab Corporation
Chicago Tribune Foundation
Chubb & Son
Citigroup Foundation
Deutsche Bank Americas
Dominion Foundation
The Duke Energy Foundation
eBay Foundation
ExxonMobil Foundation
FleetBoston Financial Foundation
Gap Foundation
Genentech
GlaxoSmithKline Foundation

ING Foundation
The Mcgraw-Hill Companies
Medco Health
Merrill Lynch & Company Foundation
The Moody's Foundation
Oracle Corporation
Pfizer Foundation
Pharmacy & Upjohn Foundation
The Prudential Foundation
SAP
Sara Lee Foundation
Sun Microsystems Foundation
Synopsys Foundation
UBS
Verizon Foundation
Wachovia Foundation
Wells Fargo

New York
Aetna Foundation
American International Group
AXA Foundation
Bristol-Myers Squibb Foundation
Computer Associates International
MONY Life Insurance Company
The Pepsi Bottling Group
Pitney Bowes Employee Giving Campaign
The Rockefeller Group
W. J. Cox Associates

Ohio
Lamson & Sessions Foundation
Nordson Corporation

Pennsylvania
Laird Technologies
The PQ Corporation
Saint-Gobain Corporation
Teleflex Foundation

Rhode Island
FM Global Foundation

South Dakota
CNA Surety

Texas
Bridgeway Capital Management
Pegasus Solutions

Virginia
America's Charities
Calbeera Systems
Gannett Foundation
Scitor Corporation

Wisconsin
Alliant Energy Foundation
Rexnord Foundation
**NFCR MANAGEMENT TEAM**

Franklin C. Salisbury, Jr  
*President*

Sujuan Ba, Ph.D.  
*Chief Operating Officer & Chief Scientific Officer*

**NFCR BOARD OF DIRECTORS**

John Slye, Ph.D.  
*Chairman*  
Slye-Hughes International, LLC  
*Virginia*

Kevin Connolly  
*Treasurer*  
Senior Vice President  
BNY Asset Management  
*New York*

Lorie Karnath  
*Managing Director*  
International Rescentris  
*Berlin, Germany*

Mark Baran  
*Major Gift Officer*  
Yale University  
*Connecticut*

Padmakumar R. Kaimal, Ph.D.  
*Director, R & D*  
Suven Life Sciences USA, LLC  
*New Jersey*

**ADVISORY BOARD**

Jamie Farr  
*Actor*  
*California*

Abraham Amoros  
*Chief of Communications*  
Office of the Governor  
*Pennsylvania*

Pamela Carter  
*Executive Vice President*  
Fleetguard, Inc.  
*Tennessee*

David Chew  
*Chief Executive Officer*  
Minimatics, Inc  
*California*

Howard D. Ellis, M.D.  
*Managing Partner*  
MedDevelopment, LLC  
*Kansas*

William Haseltine, Ph.D.  
*Former President & CEO*  
Human Genome Sciences, Inc.  
*Maryland*

Richard Mallery, Esq.  
*Partner*  
Snell & Wilmer, LLC  
*Arizona*

Ted Peters, Ph.D.  
*Interim President*  
Pacific Lutheran Theological Seminary  
*California*

William Potter  
*President*  
Robert R. Merideth, Inc.  
*New York*